Retinyl acetate(Synonyms: 视黄醇乙酸酯; Retinol acetate; Vitamin A acetate)

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Retinyl acetate (Synonyms: 视黄醇乙酸酯; Retinol acetate; Vitamin A acetate) 纯度: 99.51%

Retinyl acetate 是衍生自视黄醇的合成乙酸酯形式,具有潜在的抗肿瘤和化学预防活性。

Retinyl acetate(Synonyms: 视黄醇乙酸酯; Retinol acetate;  Vitamin A acetate)

Retinyl acetate Chemical Structure

CAS No. : 127-47-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥550 In-stock
100 mg ¥500 In-stock
500 mg ¥800 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Retinyl acetate 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Food Additive Library

生物活性

Retinyl acetate is a synthetic acetate ester form derived from retinol and has potential antineoplastic and chemo preventive activities.

分子量

328.49

Formula

C22H32O2

CAS 号

127-47-9

中文名称

维生素A乙酸酯;视黄醇乙酸酯

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Pure form -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (152.21 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.0442 mL 15.2212 mL 30.4423 mL
5 mM 0.6088 mL 3.0442 mL 6.0885 mL
10 mM 0.3044 mL 1.5221 mL 3.0442 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (7.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.61 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (6.33 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.33 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Moon, Richard C, et al. Retinyl acetate inhibits mammary carcinogenesis induced by N-methyl-N-nitrosourea. Nature. 1977 Jun 16;267(5612):620-1.

Enfuvirtide acetate(Synonyms: 醋酸恩夫韦地 T20 acetate DP178 acetate)

Enfuvirtide acetate;(Synonyms: 醋酸恩夫韦地; T20 acetate; DP178 acetate) 纯度: 97.22%

Enfuvirtide (T20; DP178) acetate 是一种抗 HIV-1 融合的抑制肽。

Enfuvirtide acetateamp;;(Synonyms: 醋酸恩夫韦地; T20 acetate; DP178 acetate)

Enfuvirtide acetate Chemical Structure

CAS No. : 914454-00-5

规格 价格 是否有货 数量
5 mg ¥600 In-stock
10 mg ¥900 In-stock
25 mg ¥1900 In-stock
50 mg ¥3400 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Enfuvirtide acetate 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide.

IC50 Target

HIV fusion[1]

体外研究
(In Vitro)

A cell-cell fusion assay reveals that the effective concentration for achieving 50% inhibition (IC50) of Enfuvirtide is 23 ± 6 nM[2]. IFN-λs (1, 2, or 3) or the antiretrovirals (AZT, Efavirenz, Indinavir, and Enfuvirtide) significantly inhibita the expression of HIV p24 antigen and Gag gene in macrophages. IFN-λs (1, 2, or 3) also enhanced the anti-HIV (Bal) effect of AZT, Efavirenz, Indinavir, and Enfuvirtide[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Enfuvirtide has a T1/2 of 3.8 h[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

4551.93

Formula

C2H4O2

CAS 号

914454-00-5

Sequence

Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2

Sequence Shortening

Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2

中文名称

醋酸恩夫韦肽;醋酸恩夫韦地

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

DMSO : 100 mg/mL (21.97 mM; Need ultrasonic)

H2O : 2 mg/mL (0.44 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.2197 mL 1.0984 mL 2.1969 mL
5 mM 0.0439 mL 0.2197 mL 0.4394 mL
10 mM 0.0220 mL 0.1098 mL 0.2197 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: 2.5 mg/mL (0.55 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (0.55 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (0.55 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (0.55 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (0.55 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.55 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Figueira TN, et al. Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. Sci Rep. 2017 Mar 30;7:45647.

    [2]. Cao P, et al. The improved efficacy of Sifuvirtide compared with Enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance. PLoS One. 2017 Feb 16;12(2):e0171567.

    [3]. Wang X, et al. IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. Front Immunol. 2017 Mar 6;8:210.

Incensole Acetate

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Incensole Acetate  纯度: 99.08%

Incensole acetate是卡氏乳香树脂的主要成分,对创伤性和缺血性颅脑损伤中的神经元损伤具有神经保护作用。Incensole acetate 减少了 hOBNSC 中由 Aβ 25-35 触发的细胞凋亡(apoptosis)。

Incensole Acetate

Incensole Acetate Chemical Structure

CAS No. : 34701-53-6

规格 价格 是否有货 数量
5 mg ¥1340 In-stock
10 mg ¥2290 In-stock
25 mg ¥4570 In-stock
50 mg ¥6860 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Incensole Acetate 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Natural Product Library
  • Covalent Screening Library
  • Terpenoids Library
  • Neuroprotective Compound Library

生物活性

Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs[1].

体外研究
(In Vitro)

Incensole acetate (100 μM; pre-treatment 4 hours) significantly ameliorates Aβ 25–35-induced cell death, a 48–52% decrease in cell viability at Aβ25–35 is restored to 85–89% upon pre-treatment with IA[1].
Incensole acetate (5-100 μM) pretreatment reverses increase in the mRNA and protein level of Bax, caspase 8, cyto c and decrease in the mRNA and protein level of Bcl2 induced by Aβ 25–35 in hOBNSCs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Human olfactory bulb neural stem cells
Concentration: 100 μM
Incubation Time: Pre-treatment 4 hours
Result: Increased hOBNSCs cell viability induced by Aβ 25-35.

分子量

348.52

Formula

C22H36O3

CAS 号

34701-53-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : 100 mg/mL (286.93 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.8693 mL 14.3464 mL 28.6928 mL
5 mM 0.5739 mL 2.8693 mL 5.7386 mL
10 mM 0.2869 mL 1.4346 mL 2.8693 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.17 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (7.17 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (7.17 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.17 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. El-Magd MA, et al. Incensole acetate prevents beta-amyloid-induced neurotoxicity in human olfactory bulb neural stem cells. Biomed Pharmacother. 2018 Sep;105:813-823.

Oxytocin acetate(Synonyms: 醋酸催产素 醋酸缩宫素 α-Hypophamine acetate Oxytocic hormone acetate)

Oxytocin acetate;(Synonyms: 醋酸催产素; 醋酸缩宫素; α-Hypophamine acetate; Oxytocic hormone acetate) 纯度: ge;99.0%

Oxytocin acetate 是一种多效的下丘脑肽 (hypothalamic peptide),有助于分娩、哺乳和亲社会行为。Oxytocin acetate 可以作为一种压力应对分子,具有抗炎、抗氧化剂和保护作用,特别是在面对逆境或创伤时。

Oxytocin acetateamp;;(Synonyms: 醋酸催产素; 醋酸缩宫素; α-Hypophamine acetate;  Oxytocic hormone acetate)

Oxytocin acetate Chemical Structure

CAS No. : 6233-83-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg) ; Apply now ;
10;mM;*;1 mL in DMSO ¥763 In-stock
5 mg ¥450 In-stock
10 mg ¥650 In-stock
50 mg ¥1200 In-stock
100 mg ¥2000 In-stock
200 mg ¥3500 In-stock
500 mg ¥7000 In-stock
1 g ; 询价 ;
5 g ; 询价 ;

* Please select Quantity before adding items.

Oxytocin acetate 相关产品

bull;相关化合物库:

  • Covalent Screening Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Metabolism/Protease Compound Library
  • FDA-Approved Drug Library
  • Human Endogenous Metabolite Compound Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Macrocyclic Compound Library
  • Endocrinology Compound Library
  • Anti-COVID-19 Compound Library
  • Orally Active Compound Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Food-Sourced Compound Library
  • Rare Diseases Drug Library
  • Childrenrsquo;s Drug Library
  • Peptide Library

生物活性

Oxytocin acetate is a pleiotropic, hypothalamic peptide known for facilitating parturition, lactation, and prosocial behaviors. Oxytocin acetate can function as a stress-coping molecule with anti-inflammatory, antioxidant, and protective effects especially in the face of adversity or trauma[1][2].

IC50 Target

Human Endogenous Metabolite

;

体内研究
(In Vivo)

During the LMA task, rat core body temperature are modestly decreased. Oxytocin acetate (subcutaneous injection; 0.1 mg/kg-0.3 mg/kg; single dose) produces significantly greater hypothermia (at 0.3 mg/kg) than either saline or the two lower doses of oxytocin. Oxytocin at 0.3 mg/kg produces a significantly greater decrease in temperature than vehicle between 15-60 min post injection, whereas 0.1 mg/kg slightly decreases temperature at the 30 min time point only[1].
Oxytocin acetate (0.1 mg/kg) engages in significantly more body sniffing and ano-genital sniffing compared with saline controls. It also increases the total time spent in social interaction (71.6±4.3 s), compared to those receiving vehicle (56.9±4.1 s)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Fifty-six male Lister-hooded rats (150–200 g)[1]
Dosage: 0.1 mg/kg-0.3 mg/kg
Administration: Subcutaneous injection; 0.1 mg/kg-0.3 mg/kg; single dose
Result: Produced significantly greater hypothermia (at 0.3 mg/kg) than the saline group.

Clinical Trial

分子量

1067.24

Formula

C45H70N12O14S2

CAS 号

6233-83-6

Sequence

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Disulfide bridge:Cys1-Cys6)

Sequence Shortening

CYIQNCPLG-NH2 (Disulfide bridge:Cys1-Cys6)

中文名称

醋酸催产素;醋酸缩宫素

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

H2O : 50 mg/mL (46.85 mM; Need ultrasonic)

DMSO : ≥ 44 mg/mL (41.23 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9370 mL 4.6850 mL 9.3700 mL
5 mM 0.1874 mL 0.9370 mL 1.8740 mL
10 mM 0.0937 mL 0.4685 mL 0.9370 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Shivali Kohli, et al. Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats. Neuropsychopharmacology. 2019 Jan;44(2):295-305.

    [2]. C Sue Carter, et al. Is Oxytocin “Nature’s Medicine”? Pharmacol Rev. 2020 Oct;72(4):829-861.

Octreotide acetate(Synonyms: 醋酸奥曲肽 SMS 201-995 acetate)

Octreotide acetate;(Synonyms: 醋酸奥曲肽; SMS 201-995 acetate) 纯度: 99.78%

Octreotide acetate是长效的天然生长抑素合成类似物,是比生长抑素更有效的生长激素胰高血糖素胰岛素的抑制剂。

Octreotide acetateamp;;(Synonyms: 醋酸奥曲肽; SMS 201-995 acetate)

Octreotide acetate Chemical Structure

CAS No. : 79517-01-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg) ; Apply now ;
10;mM;*;1 mL in DMSO ¥594 In-stock
10 mg ¥500 In-stock
50 mg ¥1116 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Octreotide acetate 相关产品

bull;相关化合物库:

  • Covalent Screening Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Immunology/Inflammation Compound Library
  • Neuronal Signaling Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Peptidomimetic Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Macrocyclic Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Endocrinology Compound Library
  • NMPA-Approved Drug Library
  • Orally Active Compound Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library
  • Peptide Library

生物活性

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently.

体内研究
(In Vivo)

Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group. Octreotide-PPSG appears to inhibit the expression of SSTR2 and SSTR5 to a greater extent than that of Octreotide-soln treated group[1]. A test dose of octreotide acetate significantly decreases the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetatea (5 mg intramuscular, q 4 wk) is initiated[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

1079.29

Formula

C51H70N10O12S2

CAS 号

79517-01-4

中文名称

醋酸奥曲肽

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro:;

DMSO : ≥ 29 mg/mL (26.87 mM)

H2O : 25 mg/mL (23.16 mM; Need ultrasonic)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9265 mL 4.6327 mL 9.2654 mL
5 mM 0.1853 mL 0.9265 mL 1.8531 mL
10 mM 0.0927 mL 0.4633 mL 0.9265 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.25 mg/mL (2.08 mM); Clear solution

    此方案可获得 ≥ 2.25 mg/mL (2.08 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.25 mg/mL (2.08 mM); Clear solution

    此方案可获得 ≥ 2.25 mg/mL (2.08 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.25 mg/mL (2.08 mM); Clear solution

    此方案可获得 ≥ 2.25 mg/mL (2.08 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Wang M, et al. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56.

    [2]. Kim S, et al. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12.

Animal Administration
[1]

Mice[1]
Thirty mice with HCC xenografts are randomLy divided into three groups: (A) Octreotide-soln group, (B) Octreotide-PPSG group, and (C) control group. Octreotide-soln group receives i.p. injection of 100 μg/kg octreotide-soln once a day and totally for consecutive 14 days. Octreotide-PPSG group receives a single subcutaneous injection of 1.4 mg/kg Octreotide-PPSG, and the injection volume is about 0.2 mL. Control group receives i.p. injection of saline once a day for consecutive 14 days. Treatment starts on the next day after injection of H22 hepatoma cell suspension and maintains for 14 days. Tumor growth is monitored by periodic caliper measurements on day 7 and day 14 post seeding. Tumor volumes (V) are calculated based on the length and width of tumor by Eq.
Rats[1]
Twelve male SD rats are divided into two groups, and housed in standard cages at 25°C, with free access to food and water for a week prior to the experiment. Rats are subcutaneously injected with Octreotidereotide solution (Octreotide-soln) or Octreotide-PPSG at an equivalent single dose of 20 mg/kg. The dose is determined based on the clinical dose of Octreotide-soln in human. Rats are fasted for 12 h before dosing and food is returned approximately 2 h post dosing. Blood samples are collected at predetermined time points using heparinized Eppendorf tubes. Immediately after collection, the blood samples are placed on ice until centrifuged at 3000 g for 10 min within 1 h. The plasma is collected and stored at −20°C until analysis.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Wang M, et al. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56.

    [2]. Kim S, et al. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12.

Alisol B 23-acetate(Synonyms: 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate)

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Alisol B 23-acetate (Synonyms: 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate) 纯度: 99.84%

Alisol B 23-acetate (23-Acetylalismol B) 是一种三萜类化合物,能够通过激活法尼醇受体促进受损的肝脏再生。

Alisol B 23-acetate(Synonyms: 23-Acetylalismol B;  23-O-Acetylalisol B;  Alisol B monoacetate)

Alisol B 23-acetate Chemical Structure

CAS No. : 26575-95-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥940 In-stock
10 mg ¥850 In-stock
50 mg ¥3100 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Alisol B 23-acetate 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Natural Product Library
  • Covalent Screening Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library

生物活性

Alisol B 23-acetate (23-Acetylalismol B), a natural triterpenoid, produces protective effects against EE-induced cholestasis, due to FXR-mediated gene regulation. IC50 Value: Target: Anti-hepatotoxic natural product. In vitro: Alisol-B 23-acetate has an effect on FXR activation in a dose-dependent manner using luciferase reporter assay in HepG2 cells [3]. In vivo: In alisol B 23-acetate-treated mice, the changes in transporters and enzymes, as well as ameliorative liver histology were abrogated by FXR antagonist guggulsterone [1]. Alisol B 23-acetate treatment in a dose-dependent manner resulted in protection against hepatotoxicity induced by CCl4via FXR activation. Through FXR activation, alisol B 23-acetate promoted hepatocyte proliferation via an induction in hepatic levels of FoxM1b, Cyclin D1 and Cyclin B1. Alisol B 23-acetate also reduced hepatic bile acids through a decrease in hepatic uptake transporter Ntcp, bile acid synthetic enzymes Cyp7a1, Cyp8b1, and an increase in efflux transporter Bsep, Mrp2 expression. In addition, alisol B 23-acetate induced the expression of STAT3 phosphorylation, and STAT3 target genes Bcl-xl and SOCS3, resulting in decreased hepatocyte apoptosis [2].

分子量

514.74

Formula

C32H50O5

CAS 号

26575-95-1

中文名称

23-乙酰泽泻醇B;泽泻醇B醋酸酯;泽泻醇B-23-醋酸酯

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (97.14 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9427 mL 9.7136 mL 19.4273 mL
5 mM 0.3885 mL 1.9427 mL 3.8855 mL
10 mM 0.1943 mL 0.9714 mL 1.9427 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.86 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.86 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.86 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Meng Q, et al. Protective effects of alisol B 23-acetate from edible botanical Rhizoma alismatis against carbon tetrachloride-induced hepatotoxicity in mice. Food Funct. 2015 Apr 8;6(4):1241-50.

    [2]. Meng Q, et al. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis. Toxicol Appl Pharmacol. 2015 Mar 15;283(3):178-86.

    [3]. Meng Q, et al. Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor. Biochem Pharmacol. 2014 Nov 15;92(2):289-98.

    [4]. Meng Q, et al. Protective Effects of Alisol B 23-Acetate Via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Estrogen-Induced Cholestatic Liver Injury in Mice. Pharm Res. 2015 Jun 4.

Angiotensin II human acetate(Synonyms: Angiotensin II acetate Ang II acetate DRVYIHPF acetate)

Angiotensin II human acetate;(Synonyms: Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate) 纯度: 99.19%

Angiotensin II human (Angiotensin II) acetate 是一种血管收缩剂,是肾素/血管紧张素系统的主要生物活性肽。Angiotensin II human acetate 在调节人类血压中起着核心作用,主要通过血管紧张素 II 与 G 蛋白偶联受体 (GPCRs)、血管紧张素II 1型受体 (AT1R) 和血管紧张素II 2型受体 (AT2R) 之间的相互作用来介导。Angiotensin II human acetate 刺激交感神经刺激,增加醛固酮生物合成和肾脏活动。Angiotensin II human acetate 诱导血管平滑肌细胞生长,增加成纤维细胞中 I 型和 III 型胶原的合成,导致血管壁和心肌增厚,并导致纤维化。Angiotensin II human acetate 也诱导细胞凋亡。Angiotensin II human acetate 通过 LOX-1 依赖的氧化还原敏感途径诱导内皮细胞毛细血管形成。

Angiotensin II human acetateamp;;(Synonyms: Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate)

Angiotensin II human acetate Chemical Structure

CAS No. : 68521-88-0

规格 价格 是否有货 数量
10;mM;*;1 mL in Water ¥910 In-stock
10 mg ¥750 In-stock
50 mg ¥3000 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Angiotensin II human acetate 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • GPCR/G Protein Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Endocrinology Compound Library
  • Neurotransmitter Receptor Compound Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Angiogenesis Related Compound Library
  • Lipid Metabolism Compound Library
  • Childrenrsquo;s Drug Library
  • Peptide Library

生物活性

Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human acetate also induces apoptosis. Angiotensin II human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway[1][2][3][4].

体外研究
(In Vitro)

Most of the known actions of Angiotensin II (Ang II) human acetate are mediated by AT1 receptors, the AT2 receptor contributes to the regulation of blood pressure and renal function[1].
Angiotensin II human acetate raises blood pressure (BP) by a number of actions, the most important ones being vasoconstriction, sympathetic nervous stimulation, increased aldosterone biosynthesis and renal actions. Other Angiotensin II human acetate actions include induction of growth, cell migration, and mitosis of vascular smooth muscle cells, increased synthesis of collagen type I and III in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. These actions are mediated by type 1 Ang II receptors (AT1)[2].
Angiotensin II (1 nM) induces the expression of LOX-1 and VEGF and enhances capillary formation from human coronary endothelial cells in Matrigel assay. Angiotensin II -mediated expression of LOX-1 and VEGF, capillary formation, intracellular reactive oxygen species generation, and phosphorylation of p38 as well as p44/42 mitogen-activated protein kinases, were suppressed by anti-LOX-1 antibody, nicotinamide-adenine dinucleotide phosphate oxidase inhibitor apocynin and the Ang II type 1 receptor blocker Losartan, but not by the Ang II type 2 receptor blocker PD123319[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Angiotensin II human (5 mL of 1 nM; intraperitoneal injection; 200-250 g Sprague-Dawley rats) acetate induces a significant neutrophil recruitment that was maximal at 4 hours and had resolved by 24 hours[4].
To distinguish the AT1 receptor population that is critical for the pathogenesis of hypertension, osmotic minipumps are implanted s.c. into each animal to infuse Angiotensin II human (1000 ng/kg/min) acetate continuously for 4 weeks. Angiotensin II human acetate causes hypertension by activating AT1 receptors in the kidney promoting sodium reabsorption[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

1106.23

Formula

C52H75N13O14

CAS 号

68521-88-0

Sequence

Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

Sequence Shortening

DRVYIHPF

中文名称

血管紧张素 II 醋酸盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

H2O : 100 mg/mL (90.40 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9040 mL 4.5199 mL 9.0397 mL
5 mM 0.1808 mL 0.9040 mL 1.8079 mL
10 mM 0.0904 mL 0.4520 mL 0.9040 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;Saline

    Solubility: 16.67 mg/mL (15.07 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. de Gasparo M, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72.

    [2]. Fyhrquist F, et al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24.

    [3]. Hu C, et al. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension. 2007;50(5):952-957.

    [4]. Nabah YN, et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004;110(23):3581-3586.

    [5]. Crowley SD, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17985-90.

Cotadutide acetate(Synonyms: MEDI0382 acetate)

Cotadutide acetate;(Synonyms: MEDI0382 acetate) 纯度: 98.01%

Cotadutide acetate (MEDI0382 acetate) 是胰高血糖素样肽-1 (GLP-1) 和胰高血糖素受体 (glucagon receptor) 的有效双重肽激动剂,EC50 值分别为 6.9 pM 和 10.2 pM。Cotadutide acetate (MEDI0382 acetate) 有促进减肥和控制血糖的能力,有潜力用于肥胖症和 2 型糖尿病 (T2D) 的研究。

Cotadutide acetateamp;;(Synonyms: MEDI0382 acetate)

Cotadutide acetate Chemical Structure

规格 价格 是否有货 数量
5 mg ¥9800 In-stock
10 mg ¥15000 In-stock
25 mg ¥28500 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Cotadutide acetate 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Clinical Compound Library
  • Drug Repurposing Compound Library
  • Diabetes Related Compound Library
  • Anti-Parkinson’s Disease Compound Library
  • Neurodegenerative Disease-related Compound Library
  • Anti-Obesity Compound Library
  • Peptide Library

生物活性

Cotadutide acetate (MEDI0382 acetate) is a potent peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptor with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate (MEDI0382 acetate) exhibits ability to facilitate both weight loss and glycaemic control, has the potential for obesity and type 2 diabetes (T2D) treatment[1].

IC50 Target

EC50: 6.9 pM (GLP-1); 10.2 pM (glucagon receptor)[1]

体外研究
(In Vitro)

Cotadutide acetate (MEDI0382 acetate) shows EC50 values of 6.9 and 10.2 pM as measured by cAMP generation in CHO cells over‐expressing human recombinant GLP‐1 or glucagon receptors in the presence of 0.1% BSA, which are within 10‐fold of the native ligands[1].
Cotadutide acetate (MEDI0382 acetate) stimulates a concentration‐dependent increase in cAMP accumulation in rat (INS‐1 832/3) and human (EndoC‐βH1) pancreatic β‐cell lines (EC50=226 pM, 1051 pM, respectively ), as well as rat, mouse and human hepatocytes (462 pM, 840 pM, 1447 pM, respectively)[1].
Cotadutide acetate (MEDI0382 acetate) has relative potency against GLP‐1R and GCGR activity in human, cynomolgus monkey, mouse and rat transfected GLP‐1 (GLP‐1R) or glucagon (GCGR) receptors expressed CHO cells, The EC50 values are 188 pM, 682 pM; 5.2 pM, 318 pM; 74 pM, 614 pM; and 50 pM, 24173 pM for Human, monkey, mouse and rat GLP‐1R and GCGR activities, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Cotadutide acetate (MEDI0382 acetate) (subcutaneous injection; 10 nmol/kg; once) robustly suppresses food intake in DIO mice relative to vehicle‐treated controls during 0‐12 hours after administration. Mean food intake is reduced during this time interval to approximately 31% of control mice treated with vehicle. The effect of MEDI0382 is evident early (0‐2 hours postdose), the terminal plasma half‐life of MEDI0382 in mice after subcutaneous administration is approximately 5 hours[1].
Cotadutide acetate (MEDI0382 acetate) (subcutaneous injection; 10 or 30 nmol/kg; once daily; 14-16 weeks) reduces body weight. reduced body weight.The mean body weight of vehicle‐treated animals increased by 2.5% of starting body weight over the course of the 4‐week study, whereas the mean body weight loss is 21%, 30% of starting body weight at dose levels of 10 nmol/kg MEDI0382, 30 nmol/kg MEDI0382, respectively [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DIO mice[1]
Dosage: 10 nmol/kg
Administration: Subcutaneous injection
Result: Showed a redction of food intake in mice after an acute administration.
Animal Model: DIO mice[1]
Dosage: 10 or 30 nmol/kg
Administration: Subcutaneous injection
Result: Reduced body weight and food intake and improves glucose tolerance in DIO mice.

Clinical Trial

分子量

3788.14

Formula

C169H256N42O57

Sequence

1′-{palmtoyl-Glu}; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp-Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly (Amide bridge: Glu1′-Lys10)

Sequence Shortening

1′-{palmtoyl-Glu}; HSQGTFTSDKSEYLDSERARDFVAWLEAGG (Amide bridge: Glu1′-Lys10)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

DMSO : 12.5 mg/mL (3.30 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.2640 mL 1.3199 mL 2.6398 mL
5 mM
10 mM

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: 1.25 mg/mL (0.33 mM); Suspended solution; Need ultrasonic

    此方案可获得 1.25 mg/mL (0.33 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: 1.25 mg/mL (0.33 mM); Suspended solution; Need ultrasonic

    此方案可获得 1.25 mg/mL (0.33 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 1.25 mg/mL (0.33 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (0.33 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Henderson SJ,et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.Diabetes Obes Metab. 2016 Dec;18(12):1176-1190.

MOTS-c(human) acetate

MOTS-c(human) acetate; 纯度: 99.57%

MOTS-c(human) acetate 是一种线粒体衍生的肽,可诱导 AMP 类似物 AICAR 的积累,增加 AMPK 的激活及其下游 GLUT4 的表达。MOTS-c(human) acetate 可诱导葡萄糖摄取并改善胰岛素敏感性,对肥胖,糖尿病,运动和长寿的调节具有影响。

MOTS-c(human) acetateamp;;

MOTS-c(human) acetate Chemical Structure

规格 价格 是否有货 数量
10 mg ¥3000 In-stock
50 mg ¥7500 In-stock
100 mg ¥12500 In-stock
200 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

MOTS-c(human) acetate 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

MOTS-c(human) acetate is a mitochondrial-derived peptide. MOTS-c(human) acetate induces the accumulation of AMP analog AICAR, increases activation of AMPK and expression of its downstream GLUT4. MOTS-c(human) acetate induces glucose uptake and improves insulin sensitivity. MOTS-c(human) acetate has implications in the regulation of obesity, diabetes, exercise, and longevity[1].

IC50 Target[1]

AMPK

;

GLUT4

;

AICAR

;

体外研究
(In Vitro)

MOTS-c inhibits the folate cycle at the level of 5Me-THF, resulting in an accumulation of AICAR [5-aminoimidazole-4-carboxamide ribonucleotide). MOTS-c also increases cellular NAD+ levels, which are also nucleotide precursors[1].
MOTS-c is a mitochondrial signal that stimulates cellular glucose uptake while suppressing respiration. The glucose taken up in response to MOTS-c is routed to the anabolic pentose phosphate pathway (PPP), which provides carbon sources for the synthesis of purines, rather than being metabolized through glycolysis. In addition, MOTS-c increases the levels of carnitine shuttles, which transport activated fatty acids into the mitochon-dria for β-oxidation, increases the level of a β-oxidation intermediate, and reduces intracellular levels of essential and non-essential fatty acids, suggesting enhanced lipid utilization; myocytes that stably overexpress MOTS-c also exhibits increased glucose uptake[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

MOTS-c injections in mice show activation of skeletal muscle AMPK and increased the level of its downstream glucose transporter GLUT4. MOTS-c may also act as a potential mitochondrial signal that mediates an exercise-induced mitohormesis response, thereby stimulating physiological adaptation and increased tolerance to exercise[1].
The primary target organ of MOTS-c appears to be skeletal muscle and fat. MOTS-c levels in mice decline with age in skeletal muscle and in circulation concomitantly with the age-dependent development of insulin resistance. Restoring MOTS-c levels by systemic injections in older mice (12 mo.) successfully reverses age-dependent skeletal muscle insulin resistance[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

2234.64

Formula

C103H156N28O24S2

Sequence

Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg

Sequence Shortening

MRWQEMGYIFYPRKLR

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

DMSO : 4 mg/mL (1.79 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.4475 mL 2.2375 mL 4.4750 mL
5 mM
10 mM

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Changhan Lee, et al. MOTS-c: A Novel Mitochondrial-Derived Peptide Regulating Muscle and Fat Metabolism. Free Radic Biol Med. 2016 Nov;100:182-187.

Larazotide acetate

Larazotide acetate; 纯度: 98.96%

Larazotide acetate 是一种合成肽,是一种紧密连接 (junction) 的调节剂。

Larazotide acetateamp;;

Larazotide acetate Chemical Structure

CAS No. : 881851-50-9

规格 价格 是否有货 数量
10;mM;*;1 mL in Water ¥2075 In-stock
1 mg ¥700 In-stock
5 mg ¥1500 In-stock
10 mg ¥2400 In-stock
25 mg ¥5200 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Larazotide acetate 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Clinical Compound Library
  • Drug Repurposing Compound Library
  • Anti-COVID-19 Compound Library
  • Cytoskeleton Compound Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Peptide Library

生物活性

Larazotide acetate is a synthetic peptide. Larazotide acetate acts as a tight junction regulator and reverses leaky junctions to their normally closed state[1].

IC50 Target

Paracellular permeability[1]

体外研究
(In Vitro)

Larazotide acetate inhibits the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells. Larazotide acetate inhibits the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells. Larazotide acetate inhibits the translocation of a gliadin 13-mer peptide, which has been implicated in celiac disease, across Caco-2 cell monolayers. Further, apically applied Larazotide acetate inhibits the increase in TJ permeability elicited by basolaterally applied cytokines[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

When tested in vivo in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibits gliadin-induced macrophage accumulation in the intestine and preserved normal tight junction structure[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

785.89

Formula

C34H59N9O12

CAS 号

881851-50-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

H2O : 16.67 mg/mL (21.21 mM; Need ultrasonic)

DMSO : 3.2 mg/mL (4.07 mM; Need ultrasonic and warming)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2724 mL 6.3622 mL 12.7244 mL
5 mM 0.2545 mL 1.2724 mL 2.5449 mL
10 mM 0.1272 mL 0.6362 mL 1.2724 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94.

Cell Assay
[1]

Caco-2 cells are seeded onto 12-well plate and grown for 21–28 days until fully differentiated. The apical and basolateral compartments of Caco-2 cell monolayers are pre-incubated in Hank’s Balanced Salt Solution (HBSS) at 37°C for 30 min. Treatment solutions containing 7.5 mM LY with or without AT-1002 (7 mM) and different concentrations of larazotide acetate (5, 10, 12.5, 15 mM) in HBSS are added to the apical compartment of each monolayer and incubated at 37°C, 50 rpm for 180 min. At the end of the incubation, samples are removed from the basolateral compartment and analyzed in a fluorescence plate reader at excitation and emission wavelengths of 485 nm and 535 nm, respectively. The increase in LY passage is calculated for each treatment and is expressed relative to that of untreated controls[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]

Cohorts of HLA-HCD4/DQ8 mice (n=10 each) are sensitized (i.p.) with 500 μg of gliadin dissolved in 0.02 mM acetic acid in 50 μg of Complete Freund’sAdjuvant; thereafter, mice are gavaged with gliadin (2 mg/mouse), +/− treatment, 2×/week for 7 weeks. Group 1 receives larazotide acetate (250 μg/mouse) and gliadin, Group 2 receives AT-1002 (250 μg/mouse) and gliadin, and Group 3 is gavaged with gliadin only. A group of non-sensitized controls (CFA, i.p. only) is gavaged with rice. Twenty-four hours after the last gavage, small intestinal tissue is mounted in Ussing chambers for the measurement of electrical parameters (Isc, conductance) and macromolecule transport (horseradish peroxidase [HRP] flux). Tissue is processed for macrophage counts by immunohistochemistry using F4/80 antibody specific for a macrophage-restricted cell surface glycoprotein[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94.